Therapeutics and DNA methylation inhibitors

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Dysregulation of cellular epigenetic machinery is linked to the pathogenesis of a number of malignancies and has been studied extensively in myelodysplastic syndromes and acute myeloid leukemia. Alteration of DNA methylation in cancer cells results in transcriptional silencing of tumor suppressor genes. DNA methyltransferase inhibitors, such as azacitidine and decitabine, have been used to reexpress these genes and have demonstrated therapeutic benefits in both benign and malignant diseases. In this chapter, we discuss the clinical application of demethylating agents, the data that have led to their approval in hematologic diseases, and the future potential uses of these agents, both alone and in combination.

Original languageEnglish
Title of host publicationMedical Epigenetics
Number of pages11
ISBN (Electronic)9780128239285
StatePublished - 1 Jan 2021


  • Acute myeloid leukemia
  • Azacitidine
  • DNA methyltransferase inhibitors
  • Decitabine
  • Hypomethylating agents
  • Myelodysplastic syndromes


Dive into the research topics of 'Therapeutics and DNA methylation inhibitors'. Together they form a unique fingerprint.

Cite this